Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors
US11266648B2 · kind B2 · utility
0Cited by
3References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 27, 2020 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Apr 27, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2121/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides, inter alia, compounds of general formula (I) capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.